Molecular markers such as amyloid PET, cerebrospinal fluid (CSF) Aβ, and CSF tau are frequently employed in the clinical diagnosis of AD, and biomarkers are increasingly recognized as integral components of the drug development pipeline [10]. This evidence concerns the gene MAPT and amyloidosis.